Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics

ClinicalTrials.gov Identifiers: NCT03569293 (Measure Up 1), NCT03607422 (Measure Up 2) and NCT03568318 (AD Up).